Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents

Molecules

Volumn 17, Issue 6, 2012, Pages 7556-7568

  Li, Dahong ^a   Wang, Lei ^a   Cai, Hao ^a   Zhang, Yihua ^a   Xu, Jinyi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti tumor agents; Hybrid; NO donor; Oridonin; SAR

Indexed keywords

1,2,5 OXADIAZOLE 2 OXIDE; 1,2,5-OXADIAZOLE 2-OXIDE; ANTINEOPLASTIC AGENT; KAURANE DERIVATIVE; NITRIC OXIDE DONOR; ORIDONIN; OXADIAZOLE DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CELL STRAIN K 562; CHEMISTRY; DRUG EFFECT; HUMAN; IC 50; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES, KAURANE; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; NITRIC OXIDE DONORS; OXADIAZOLES;

EID: 84862995584     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17067556     Document Type: Article

References (22)

1. Mocellin, S. Nitric oxide: Cancer target or anticancer agent? Curr. Cancer Drug Targets 2009, 9, 214-236.
2. Ignarro, L. J. Signal transduction mechanisms involving nitric oxide. Biochem. Pharmacol. 1991, 41, 485-490.
3. Fukuto, J. M.; Wink, D. A. Nitric oxide (NO): Formation and biological roles in mammalian systems. Met. Ions Biol. Syst. 1999, 36, 547-595.
4. Wink, D. A.; Ridnour, L. A.; Hussain, S. P.; Harris, C. C. The reemergence of nitric oxide and cancer. Nitric Oxide 2008, 19, 65-67. (Pubitemid 351970245)
5. Hirst, D.; Robson, T. Nitric oxide in cancer therapeutics: Interaction with cytotoxic chemotherapy. Curr. Pharm. Des. 2010, 16, 411-420.
6. Millet, A.; Bettaieb, A.; Renaud, F.; Prevotat, L.; Hammann, A.; Solary, E.; Mignotte, B.; Jeannin, J. F. Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. Gastroenterology 2002, 123, 235-246. (Pubitemid 34747544)
7. Postovit, L. M.; Adams, M. A.; Lash, G. E.; Heaton, J. P.; Graham, C. H. Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int. J. Cancer 2004, 108, 47-53. (Pubitemid 37444442)
8. Findlay, V. J.; Townsend, D. M.; Saavedra, J. E.; Buzard, G. S.; Citro, M. L.; Keefer, L. K.; Ji, X.; Tew, K. D. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxidereleasing prodrug. Mol. Pharmacol. 2004, 65, 1070-1079. (Pubitemid 38543478)
9. Yasuda, H.; Yamaya, M.; Nakayama, K.; Sasaki, T.; Ebihara, H.; Kanda, A.; Asada, M.; Inoue, D.; Suzuki, T.; Okazaki, T.; et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-smallcell lung cancer. J. Clin. Oncol. 2006, 24, 688-694. (Pubitemid 46630435)
10. Siemens, D. R.; Heaton, J. P.; Adams, M. A.; Kawakami, J.; Graham, C. H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009, 74, 878-883.
11. Moharram, S.; Zhou, A.; Wiebe, L. I.; Knaus, E. E. Design and synthesis of 3'-and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: Biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents. J. Med. Chem. 2004, 47, 1840-1846. (Pubitemid 38380928)
12. Maksimovic-Ivanic, D.; Mijatovic, S.; Harhaji, L.; Miljkovic, D.; Dabideen, D.; Fan Cheng, K.; Mangano, K.; Malaponte, G.; Al-Abed, Y.; Libra, M.; et al. Anticancer properties of the novel nitric oxide-donating compound (S, R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol. Cancer Ther. 2008, 7, 510-520. (Pubitemid 351482134)
13. Chen, L.; Zhang, Y.; Kong, X.; Lan, E.; Huang, Z.; Peng, S.; Kaufman, D. L.; Tian, J. Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid. J. Med. Chem. 2008, 51, 4834-4838.
14. Lai, Y.; Shen, L.; Zhang, Z.; Liu, W.; Zhang, Y.; Ji, H.; Tian, J. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as antihepatocellular carcinoma agents. Bioorg. Med. Chem. Lett. 2010, 20, 6416-6420.
15. Ling, Y.; Ye, X.; Ji, H.; Zhang, Y.; Lai, Y.; Peng, S.; Tian, J. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents. Bioorg. Med. Chem. 2010, 18, 3448-3456.
16. Ling, Y.; Ye, X.; Zhang, Z.; Zhang, Y.; Lai, Y.; Ji, H.; Peng, S.; Tian, J. Novel nitric oxidereleasing derivatives of farnesylthiosalicylic acid: Synthesis and evaluation of antihepatocellular carcinoma activity. J. Med. Chem. 2011, 54, 3251-3259.
17. Tang, X.; Gu, X.; Ai, H.; Wang, G.; Peng, H.; Lai, Y.; Zhang, Y. Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells. Bioorg. Med. Chem. Lett. 2012, 22, 801-805.
18. Kang, N.; Zhang, J. H.; Qiu, F.; Chen, S.; Tashiro, S.; Onodera, S.; Ikejima, T. Induction of G (2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J. Nat. Prod. 2010, 73, 1058-1063.
19. Xu, J.; Yang, J.; Ran, Q.; Wang, L.; Liu, J.; Wang, Z.; Wu, X.; Hua, W.; Yuan, S.; Zhang, L.; et al. Synthesis and biological evaluation of novel 1-O-and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg. Med. Chem. Lett. 2008, 18, 4741-4744.
20. Wang, L.; Ran, Q.; Li, D.; Yao, H.; Zhang, Y.; Yuan, S.; Zhang, L.; Shen, M.; Xu, J. Synthesis and anti-tumor activity of 14-O-derivatives of natural oridonin. Chin. J. Nat. Med. 2011, 9, 194-198.
21. Wang, L.; Li, D.; Wang, C.; Zhang, Y.; Xu, J. Recent progress in the development of natural ent-kaurane diterpenoids with anti-tumor activity. Mini-Rev. Med. Chem. 2011, 11, 910-919.
22. Wang, L.; Li, D.; Xu, S.; Cai, H.; Yao, H.; Zhang, Y.; Jiang, J.; Xu, J. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: Synthesis and biological evaluation of ent-6, 7-seco-oridonin derivatives as novel potential anticancer agents. Eur. J. Med. Chem. 2012, 52, 242-250.